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Partial epilepsies have a substantial heritability. However, the actual genetic causes are largely unknown. In contrast to many
other common diseases for which genetic association-studies have successfully revealed common variants associated with
disease risk, the role of common variation in partial epilepsies has not yet been explored in a well-powered study. We under-
took a genome-wide association-study to identify common variants which influence risk for epilepsy shared amongst partial
epilepsy syndromes, in 3445 patients and 6935 controls of European ancestry. We did not identify any genome-wide significant
association. A few single nucleotide polymorphisms may warrant further investigation. We exclude common genetic variants
with effect sizes above a modest 1.3 odds ratio for a single variant as contributors to genetic susceptibility shared across the
partial epilepsies. We show that, at best, common genetic variation can only have a modest role in predisposition to the partial
epilepsies when considered across syndromes in Europeans. The genetic architecture of the partial epilepsies is likely to be very
complex, reflecting genotypic and phenotypic heterogeneity. Larger meta-analyses are required to identify variants of smaller
effect sizes (odds ratio51.3) or syndrome-specific variants. Further, our results suggest research efforts should also be directed
towards identifying the multiple rare variants likely to account for at least part of the heritability of the partial epilepsies. Data
emerging from genome-wide association-studies will be valuable during the next serious challenge of interpreting all the
genetic variation emerging from whole-genome sequencing studies.
Keywords: partial epilepsy; genome-wide association; genetics; common variants
Abbreviation: SNP = single nucleotide polymorphism
Introduction
The epilepsies constitute the commonest serious chronic neuro-
logical condition, with a prevalence of 3–16 per 1000 worldwide
(Begley et al., 2007). Mendelian epilepsies probably account for
only 1% of cases. The majority—so-called ‘sporadic’ epilepsies—
are considered ‘complex’: both genetic and environmental factors
probably play a role, to different extents, in individual patients.
Estimates of partial epilepsy heritability vary between studies,
some estimates reaching 70% (Kjeldsen et al., 2001). All published
twin and family studies report higher concordance among mono-
zygotic than dizygotic twins and high familial aggregation (e.g.
Berkovic et al., 1998; Miller et al., 1998; Hemminki et al.,
2006). Nevertheless, even though the importance of genetic fac-
tors is clear, the factors themselves remain elusive. Numerous can-
didate gene studies have failed to identify unambiguous
associations (see Discussion section in Tan et al., 2004; Cavalleri
et al., 2005, 2007). The failure to detect robust associations has
been commonly attributed to small sample sizes and hence low
study power, and to the choice of candidate genes. Many studies
focused on candidates emerging from the genetics of familial
epilepsies, such as ion-channel genes, which comprise two-third
of genes responsible for Mendelian epilepsies. Interestingly, in
single-gene mutant mice exhibiting spontaneous or more
readily-evoked seizures, only a quarter of the mutated genes
encode ion channels (Frankel, 2009), suggesting a much broader
spectrum of pathways and genes for seizure predisposition than
currently known.
Despite the heterogeneity of partial epilepsy syndromes, some
shared biological features, such as some components of seizures,
secondary generalization of partial seizures, shared EEG abnorm-
alities and the fundamental biophysical and neurochemical cellular
components of seizures, e.g. action potentials and synaptic trans-
mission processes, suggest there are some common mechanisms
for susceptibility to partial seizures in general. Studies indicate that
different types of epilepsy can aggregate in families (Ottman
et al., 1998; Bianchi et al., 2003; Berkovic et al., 2004), suggest-
ing the existence of shared genetic factors that increase sus-
ceptibility to different epilepsies. More recently, microdeletion
analyses have shown that apparently the same genetic defect
can contribute to different forms of epilepsy (de Kovel et al.,
2009), including ‘symptomatic’ epilepsies (Heinzen et al., 2010).
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It is possible, therefore, that shared genetic variants predispose to
partial epilepsies, irrespective of syndrome type or any structural
cause. Knowledge of such shared variants would significantly in-
crease the understanding of disease biology of partial epilepsies
and help identify targets for novel therapeutic interventions effect-
ive across partial epilepsies. On the other hand, if well-powered
and comprehensive studies cannot detect any common genetic
variants for susceptibility for partial epilepsies, our concepts of
the genetic architecture of partial epilepsies will evolve, and a
different approach may prove more productive in epilepsy genetics
research.
Here we report the results from a genome-wide association-
study for partial epilepsies in a large cohort of patients of
European ancestry. We show that common variants are unlikely
to have clinically relevant effects in predisposition to partial epi-
lepsies shared across syndromes.
Methods
Patients
Patients with partial epilepsies were recruited in seven countries
(Supplementary material) during clinical appointments. The diagnosis
of partial epilepsy was made and/or reviewed by a consultant epilep-
tologist who was part of this study, with access to clinical history and
available investigation results. The International League Against
Epilepsy (Commission on Classification and Terminology of the
International League Against Epilepsy, 1989) definition for partial
epilepsy was used. A patient was considered as having epilepsy if
he/she had had two or more unprovoked epileptic seizures. Partial
epilepsy was defined as epilepsy characterized by seizures the
semiology or investigation (ictal EEG) of which disclosed a focal
origin of seizures. We did not select patients by syndrome other
than partial epilepsy, nor by known structural abnormality, if any.
Phenotypic details of the patients for each country’s cohort are
shown in Table 1, using a scheme adapted from The International
League Against Epilepsy revised organization of phenotypes in
epilepsies (Berg et al., 2010).
Informed consent was obtained from study participants and the
study was approved by the Ethics Committee at each recruitment
site according to national standards. Patients of all ethnicities were
recruited and genotyped. However, only patients of European ancestry
were included in genome-wide association analysis to minimize con-
founding by population structure (see below).
Controls
We used (Supplementary Fig. 1): (i) 288 controls from Finland and 285
controls from Switzerland without neurological conditions, recruited
and genotyped for this study; (ii) 1165 USA controls from the Duke
Memory study (Need et al., 2009; Cirulli et al., 2010), who consented
to participate in epilepsy genetics research; 84% of participants filled
in a questionnaire about their history of neurological conditions and
the subjects who reported a history of seizures were excluded from the
study; (iii) 5667 population controls from the Wellcome Trust Case
Control Consortium (2007) Phase 2, September 2009 data release;
(iv) 469 population controls from Finland, all 85-years-old or over at
the time of recruitment (Vantaa85+) (Myllykangas et al., 2005;
Peuralinna et al., 2008); and (v) 211 Irish neurologically-normal con-
trols from the Study of Irish Amyotrophic Lateral Sclerosis (Cronin
et al., 2008).
Genotyping and quality control
DNA was extracted from blood samples using standard procedures. All
patients with epilepsy and the Switzerland, Finland and USA controls
were genotyped at Duke University. The majority of the in-house
genotyped patients (93.4%) and controls (77.4%) were genotyped
using Human610-Quadv1genotyping chips (Table 2). Genotype calling
and quality control were performed using Beadstudio v3 software as
previously described (Fellay et al., 2007) and detailed in the
Supplementary material. Finnish control data from the Vantaa85+
study were received in Beadstudio files and processed using the
same protocol.
Quality control procedures were applied to the Wellcome Trust Case
Control Consortium control dataset in the following order: (i) all indi-
viduals listed as ’individual exclusions’ in the data release documenta-
tion were excluded; (ii) any remaining individuals with42% missing
data were removed; (iii) single nucleotide polymorphisms (SNPs) with
41% missing data were removed; (iv) SNPs with Hardy-Weinberg
equilibrium P-value below 11010 were removed; (v) allele frequen-
cies in 1958 birth cohort and National-Blood cohort subsets were
compared using the 2 test, and SNPs with P-values below
1 1010 were removed; and (vi) principal component analysis was
performed on the remaining data using a subset of unlinked SNPs to
check for possible plate effects. Such effects were suspected in two
plates and these samples were removed (Supplementary material).
The Irish control genotype data were downloaded from the dbGaP
database (http://www.ncbi.nlm.nih.gov/gap), dbGaP accession
number phs000127.v1.p1. SNPs with call rates below 0.98 and cluster
separation values below 0.3, as provided in the data release documen-
tation, were removed. We then checked that none of the individuals
had42% missing data.
Further, we performed gender and relatedness checks for all samples
and manually inspected cluster plots for a subset of SNPs as described
in the Supplementary material.
Population ancestry and stratification
analysis
A combination of self-identified ancestry and EIGENSTRAT principal
components methods (Price et al., 2006) were used to identify indi-
viduals of European ancestry and to correct further for population
stratification. We used a modified EIGENSTRAT method, as previously
described (Fellay et al., 2007) and detailed in the Supplementary
material.
Principal component analysis also detects correlations in the data
that may occur for reasons other than population ancestry.
Correlations among individuals may be due to laboratory processing
error (batch or plate effects). Correlations among SNPs may be due to
large linkage disequilibrium regions or genotype calling differences
(e.g. genotyping chip differences or different genotype call algo-
rithms). Therefore, we inspected all EIGENSTRAT axes for these effects
and suspect samples were removed. Similarly, we detected 31 SNPs
discordant between HumanHap550 and Human610-Quadv1 chips and
removed them from the analysis.
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Association analysis
Only SNPs present on both Illumina Human610-Quadv1 and
Human1-2M-DuoCustom were included in the analysis. Association
analysis was performed using PLINK (Purcell et al., 2007). First, we
used the logistic regression additive model, including gender and all
significant EIGENSTRAT axes, as assessed using the Tracy-Widom stat-
istic with P50.05, as covariates into the model. Further, we performed
a stratified analysis using the Cochran–Mantel–Haenszel test. For this
analysis, seven strata were used, each corresponding to the recruit-
ment country. To ensure homogeneity of each stratum, we performed
principal component analysis within each stratum separately and
removed the outliers.
Only SNPs with minor allele frequency of 1% and above were
included in the analysis. We chose this frequency cut-off because
we were interested in common variants. Our study was underpowered
to detect associations with lower allele frequencies. Genotypes of SNPs
with minor allele frequency51% were less reliably called across the
different cohorts.
Power calculations were performed using PGA Power Calculator
software (Menashe et al., 2008) assuming a disease prevalence of
0.5%, the additive risk model, and r2 0.9 between a causal variant
and a genotyped marker (Fig. 1).
Gene ontology analysis was performed using the ALIGATOR
method (Holmans et al., 2009) to investigate whether there was
enrichment for SNPs in genes in any gene ontology categories
among the SNPs with low, but not genome-wide significant,
P-values. We investigated these SNP sets using two thresholds,
P50.0001 and P50.001. Only SNPs located within genes were
included (based on NCBI SNP build 129 and NCBI sequence build
36.3). One SNP per gene, with the lowest P-value, was included in
the ALIGATOR analysis using 20 000 simulated replicate gene lists and
5000 simulated replicate studies.
Results
Study participants (total 4514, 3941 patients with partial epilepsies
and 573 controls) were genotyped in the study (Supplementary
Fig. 1). 4383 (97.1%, 3816 patients and 567 controls) passed
genotyping quality control filters. After the application of quality
Table 2 Subjects of European ancestry included in the analysis
Country Number of
subjects in
analysis
Percent of
females
(number)
Genotyping chip
(number of samples)
Patients
UK 1185 51.1 (605) Human610-Quadv1 (1018), HumanHap550v3 (167)
Ireland 607 51.1 (310) Human610-Quadv1 (562), HumanHap300v1 (45)
Belgium 418 53.1 (222) Human610-Quadv1 (418)
Finland 410 59.0 (242) Human610-Quadv1 (410)
USA 393 55.2 (217) Human610-Quadv1 (393)
Norway 201 55.7 (112) Human610-Quadv1 (201)
Switzerland 231 50.2 (116) Human610-Quadv1 (231)
All patients 3445 52.9 (1824) Human610-Quadv1 (3233),
HumanHap550v3 (167), HumanHap300v1 (45)
Controls
UK 5116 49.6 (2535) Human1-2M-DuoCustom (5116)
Finland 746 72.9 (544) Human610-Quadv1 (277), Human1M-Duov3 (104),
HumanCNV370-Quadv3 (171), HumanCNV370v1 (194)
USA 605 56.9 (344) Human610-Quadv1 (347), HumanHap550v3 (81),
HumanHap550v1 (171), Human1Mv1 (6)
Switzerland 259 56.8 (147) Human610-Quadv1 (259)
Ireland 209 46.9 (98) HumanHap550v3 (209)
All controls 6935 52.9 (3668) Human610-Quadv1 (883), Human1-2M-DuoCustom (5116), HumanHap550v3 (81),
HumanHap550v1 (380), Human1Mv1 (6), Human1M-Duov3 (104),
HumanCNV370-Quadv3 (171), HumanCNV370v1 (194)
Figure 1 Minimal detectable odds ratio at P= 5 108 for
different power levels in our genome-wide association-study.
Power calculations were performed assuming a disease preva-
lence of 0.5%, the additive risk model and r2= 0.9 between a
causal variant and a genotyped marker.
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control procedures, the average genotyping call rate was 99.96%
for subjects genotyped on Human610-Quadv1 chips and 99.93%
for subjects genotyped on HumanHap550v3 chips. Thirty-four
known duplicate samples were genotyped. Genotype concordance
rate was499.99% regardless of whether samples were genotyped
on the same chip type or on different chips. Twenty subjects
(0.4%, 17 patients and three controls) were excluded because
sex mismatch was detected between phenotype and genotype
data. One sample was removed because the same patient
was recruited independently in two cohorts (UK and Ireland). A
further 48 subjects (27 patients and 21 controls) were removed
because of imputed relatedness to other study participants. The
resulting dataset was merged with the quality-controlled control
datasets from the Duke Memory study, Wellcome Trust Case
Control Consortium, Vantaa85+ and Study of Irish Amyotrophic
Lateral Sclerosis, and a further three related controls were
removed.
After the population structure analysis, 3445 patients with
partial epilepsies and 6935 controls of European ancestry were
included for genome-wide association-analysis (Table 2). 528 745
SNPs were included in the analysis. We note, however, that
for the SNPs which were on Human610-Quadv1 and Human1-
2M-DuoCustom only, but not on other types of chips, the sample
size was smaller. Therefore the minimal sample size was 3233
patients and 5999 controls, if a SNP was not present on any
other type of the chip.
First, we performed association analysis using logistic regression,
including sex and 15 EIGENSTRAT axes as covariates in an additive
genetic model. Inspection of quantile–quantile plots showed a
slight departure from ‘normal’ expectation (Fig. 2A) with a gen-
omic inflation factor  1.05. This could indicate the existence of
many causal alleles with small effect sizes. However, we were
concerned there could be residual population stratification.
Unequal sample sizes from different European subpopulations
can bias principal component-based population structure
analysis, overemphasizing variation within the largest cohorts.
Also, because of the differences in ratio of patients and controls
from the different populations, the most significant principal com-
ponent axes correlated with case–control status. Therefore
principal component-based correction could have over-
compensated. To check the robustness of the association results,
we performed a stratified association analysis using the Cochran–
Mantel–Haenszel test. The quantile–quantile plot indicated a
slight excess of low P-values, with a genomic inflation factor
 1.02 indicating adequate correction for population structure
(Fig. 2B).
Manhattan plots of the genome-wide association-results are
shown in Fig. 3. Results for SNPs with P-values below 5105
in both analyses are shown in Table 3. All SNPs with P-values
below 1104 in either Cochran–Mantel–Haenszel or logistic re-
gression tests are shown in the Supplementary material. The
P-values for all SNPs are available from http://www.ion.ucl.ac.
uk/departments/epilepsy/themes/genetics/PEvsCTRL.
None of the P-values in our study reach the now
widely-accepted 5108 threshold for genome-wide significance
in association studies (McCarthy et al., 2008), nor the 9.46108
threshold required to achieve significance after applying Bonferroni
correction for 528 745 tests in our study specifically.
The top SNP, rs346291, (P= 3.34107) is located on chromo-
some 6 within a predicted pseudogene and is located 95 and
116 kb from the closest known genes, SH3BGRL2 and ELOVL4,
respectively. There is little linkage disequilibrium in the region, and
the second most-associated SNP, rs9341799, is in only moderate
linkage disequilibrium with rs346291 (r2= 0.34 in our dataset)
(Fig. 4). To test the independence of association signals for
these two SNPs, we performed logistic regression analysis for
rs9341799 conditioned on the genotype of rs346291, i.e. incor-
porating this genotype as a covariate in the model. We detected a
Figure 2 Quantile–quantile plots of P-values (red dots) of genome-wide association-analysis in partial epilepsies based on P-values
calculated using logistic regression and including significant EIGENSTRAT axes as covariates (A) and using the Cochran–Mantel–Haenszel
test (B). Figure generated in WGAviewer (Ge et al., 2008).
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residual association (P= 0.0102), indicating that these two signals
are not completely dependent on each other.
The other top associated SNPs lie within interesting candidate
genes and may warrant further investigation. The third
most-associated SNP, rs2601828 (P= 1.21 106) is an intronic
SNP in the ADCY9 gene, encoding adenylate cyclase 9, which
catalyses the formation of cyclic AMP from ATP and is involved
in neuronal signalling. The PRKCB gene, which encodes protein
kinase C, also involved in neuronal signalling, is another interesting
candidate. However, we note that these associations did not reach
genome-wide significance in our study and require replication in
an independent study.
Further, we performed gene ontology analysis to see whether
any gene ontology categories are overrepresented among genes
with SNPs with low P values (Holmans et al., 2009). Ion-channel
and receptor coding genes showed significant enrichment
(Tables 4 and 5).
Discussion
The contribution of genetic factors to sporadic partial epilepsies is
undoubted, but the identity of these factors remains almost en-
tirely unknown. We show that, for modest (or greater) effect
sizes, common SNPs appear not to contribute to causation
shared across the partial epilepsies. Previous failed attempts to
identify associated variants (including our own) have usually
been attributed to small sample sizes coupled with a candidate
gene approach, which necessarily relies on the limited existing
biological understanding of epilepsy. However, despite the
less-biased genome-wide approach and a large cohort, with over
80% power to detect common variants with odds ratio above
1.25–1.3, and close to 100% power to detect common variants
with odds ratio above 1.35–1.4 (Fig. 1), we still did not detect
genome-wide significant associations. The genotyping platform
used has a high genomic coverage—the markers, spaced evenly
throughout the genome, tag 87% of common variants (with
minor allele frequency above 0.05) with r240.8, and 95% with
r2 of at least 0.55 in European populations (Illumina technical
note, based on HapMap release 24 data, www.illumina.com).
Although it is possible that we failed to detect real associations
with common variants with high effect sizes, if these variants were
not represented or poorly tagged, it is highly unlikely that we
missed multiple associations, such as are predicted by the
common variant—common disease model, and found in many
other complex diseases (e.g. Wellcome Trust Case Control
Consortium, 2007). Therefore, it is unlikely that there is any
shared common genetic causation for the partial epilepsies that
acts across syndromes in European populations.
We only investigated genetic factors shared across partial epi-
lepsies, disregarding the type of partial epilepsy. The differing risks
of epilepsy in first-degree relatives of those with idiopathic or
cryptogenic partial epilepsy compared to those with symptomatic
partial epilepsy have led to the suggestion that genetic influences
are primarily restricted to the idiopathic and cryptogenic subgroups
(Ottman et al., 1996; Bianchi et al., 2003). Heritabilities vary even
among ‘idiopathic’ partial epilepsy syndromes; for example, in-
herited factors seem to play only a minor role in benign epilepsy
with centrotemporal spikes (Vadlamudi et al., 2006). Notably, the
distinction between ’idiopathic’, ’cryptogenic’ and ’symptomatic’ is
not always obvious. For example, in some older studies, MRI qual-
ity (if MRI had indeed been undertaken) might have been such
that some ’symptomatic’ were misclassified as ’idiopathic’ or
’cryptogenic’. In addition, the recent organization of the epilepsies
recommended by the International League Against Epilepsy dis-
courages the use of these terms (Berg et al., 2010). Since the
majority of patients in our study were recruited in tertiary clinical
centres, our cohort might have included more patients with more
severe, lesion-associated epilepsies that may have lower heritabil-
ities, in comparison to the general population of patients with
epilepsy, from which heritability estimates are predominantly
derived (Kjeldsen et al., 2001).
Figure 3 Manhattan plots for genome-wide association-analysis results. log10 P-values of the logistic regression test (A) and the
Cochran–Mantel–Haenszel test (B) for quality-control-positive SNPs are plotted against SNP positions on each chromosome.
Chromosomes are shown in alternating colours for clarity.
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Given these considerations, it is possible that syndrome-specific
common genetic causes do exist, and that a genome-wide
association-study in a more homogeneous and narrowly-defined
group of patients might detect them. Gathering patients with a
single syndrome in cohorts big enough for adequately-powered
genome-wide association-studies will be challenging, especially if
population structure is also considered.
There may yet be susceptibility loci shared across the partial
epilepsies, but with comparatively small (51.35) effect sizes, a
phenomenon observed for both normal traits [e.g. height
(Soranzo et al., 2009), pulmonary function (Hancock et al.,
2010)] and other common diseases [e.g. obesity (Willer et al.,
2009), diabetes (Barrett et al., 2009)]. Discovery of such
small-effect variants is unlikely to have immediate clinical applica-
tion, but could be illuminating for disease biology.
For detection of common causative variants specific to partial
epilepsy syndromes, or those of small effect size shared across the
partial epilepsies, the assembly of much larger cohorts will be
necessary as has been successfully achieved for other conditions,
such as diabetes (Barrett et al., 2009) and multiple sclerosis
(De Jager et al., 2009). Such an effort is underway for
meta-analysis of genetic data in epilepsy, and we urge all interested
groups with data to join in with this important effort (please contact
Prof. S. Berkovic, Chair, Genetics Commission, International
League Against Epilepsy: s.berkovic@unimelb.edu.au). The top
hits in our study, as well as the gene ontology analysis results,
hint at possible insights into mechanisms in the partial epilepsies
and may warrant further investigation—but this will also require
larger cohorts. It is now difficult to justify smaller, under-powered,
genome-wide association-studies of susceptibility to partial epilep-
sies in pan-syndromic cohorts of European ancestry.
We only investigated patients of European ancestry. The types
and proportions of acquired epilepsies with known causes differ
across populations. For example, the higher rates of epilepsy in
some developing countries are thought mainly to be due to neu-
rocysticercosis (Garcı´a et al., 2003). It is also possible that due to
genetic differences between populations, genetic factors influen-
cing susceptibility to sporadic partial epilepsies also differ. But it is
still likely that large cohorts will be needed to discover such vari-
ants or to exclude their role in partial epilepsies in populations of
other ethnicities.
More broadly, these results suggest the need to re-evaluate
strategies for detection of causal genetic variants in the partial
epilepsies: the genetic and mechanistic architecture of the partial
epilepsies must be more complex or heterogeneous than con-
sidered here. In contrast to the common variant-common disease
approach, recent discoveries of putatively-causal structural
abnormalities (e.g. de Kovel et al., 2009, Heinzen et al., 2010)
show that rare variants with large effect sizes can cause a broad
spectrum of epilepsies, and can even manifest with different
neuropsychiatric conditions. Therefore, it seems likely that rare,
or even individual, variants might constitute a substantial propor-
tion of genetic causes in partial epilepsies, accounting for the
‘missing heritability’ (Manolio et al., 2009). Similar findings have
emerged in other neuropsychiatric conditions (Merikangas et al.,
2009).T
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Figure 4 Overview of chromosome 6 region with top associated SNPs. Top: log10 P-values for Cochran–Mantel–Haenszel test, each bar
represents a SNP; bottom: linkage disequilibrium structure for this region in HapMap CEU samples, colouring according to r2. Figure
generated in WGAviewer (Ge et al., 2008).
Table 4 Results of gene ontology analysis for partial epilepsies associated SNPs with P50.0001
(Cochran–Mantel–Haenszel test), gene ontology categories with enrichment P50.05
Gene
ontology
number
Type Total
number genes
in category
Number of
genes on list
Expected
number of
genes on list
P-value Function
GO:0005230 FUNCTION 69 3 0.3 0.0032 Extracellular ligand-gated ion channel activity
GO:0005234 FUNCTION 19 2 0.2 0.016 Extracellular-glutamate-gated ion channel activity
GO:0004970 FUNCTION 18 2 0.2 0.016 Ionotropic glutamate receptor activity
GO:0015276 FUNCTION 112 3 0.58 0.019 Ligand-gated ion channel activity
GO:0022834 FUNCTION 112 3 0.58 0.019 Ligand-gated channel activity
GO:0005231 FUNCTION 46 2 0.23 0.021 Excitatory extracellular ligand-gated ion channel activity
GO:0004888 FUNCTION 832 6 2.28 0.022 Transmembrane receptor activity
GO:0044248 PROCESS 839 4 1.22 0.032 Cellular catabolic process
GO:0046982 FUNCTION 125 2 0.29 0.032 Protein heterodimerization activity
GO:0045211 CELLULAR 115 3 0.72 0.035 Postsynaptic membrane
GO:0022836 FUNCTION 277 4 1.25 0.035 Gated channel activity
GO:0016788 FUNCTION 547 4 1.27 0.036 Hydrolase activity, acting on ester bonds
GO:0000122 PROCESS 148 2 0.31 0.039 Negative regulation of transcription from RNA
polymerase II promoter
GO:0008066 FUNCTION 29 2 0.32 0.040 Glutamate receptor activity
GO:0005529 FUNCTION 145 2 0.32 0.041 Sugar binding
GO:0009056 PROCESS 952 4 1.41 0.049 Catabolic process
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Our study provides further support for a rare variant(s)—
common disease model (Iyengar and Elston, 2007). We did
detect a slight excess of SNPs with borderline significant P-
values, and our most associated SNPs suggest multiple independ-
ent signals clustered in the same genomic region. The strongest
signals in our study are generated by two SNPs in only moderate
linkage disequilibrium with each other (r2= 0.34) and the associ-
ation is not completely explained by either SNP alone. Such inde-
pendent signals of common variants are the typical features of
‘synthetic’ associations (Dickson et al., 2010), actually caused by
one or several rare variants with larger effect sizes. Although the
causal variants can be located at relatively long distances from the
‘associated’ common alleles, the detected common variant associ-
ations are the best available pointers to the genomic regions
where some of the ‘missing heritability’ of partial epilepsies
might lie.
The results of our study, combined with emerging knowledge
from studies of rare structural variants, strongly promote a shift to
the next stage of epilepsy genetics—not only large meta-analyses,
but also the search for rare variants with larger effects using
exome or whole-genome sequencing. The raw data from
genome-wide association-studies, such as ours, can provide a
powerful tool with which upcoming sequencing findings could
be more successfully interpreted.
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